Download Dendritic Cell Cancer Vaccine Market & Clinical Trials Insight Report

Cancer is a disease caused by the uncontrolled division of the normal body cell, when these cells lose their property of contact inhibition or the ability to know when to stop dividing, they become cancerous. A vaccine generally aims at activating the immune cells to fight against a particular antigen. This specificity of the vaccination to target and kill the infected cells is responsible for its healing property. However the same cannot be done for the cancer cells, reason being that the immune cell does not recognize the cancer cells as a foreign antigen and thus does not attempt to get rid of it. This makes cancer a serious threat to the body’s immune system.

Dendritic cells are the professional antigen presenting cells of the immune system that have been used as a vaccine in cancer patient to induce a tumor specific T-helper response. The reason for the popularity of the dendritic cell cancer vaccine is that research has shown that during clinical trials even patient suffering from the final stage four cancer showed response to the dendritic cell cancer treatment which suggests that it could lead to the production of a novel vaccine that could be the solution to the treatment of cancer.

The first dendritic cell cancer vaccine to be approved by FDA was known Provenge, for prostate cancer. This is the only drug currently in the FDA approved list. It was the success of this vaccine which grabbed the attention of marketers and investors as it showed promising potential and scope of significant growth in the near future. Development of allogeneic based dendritic cells has been receiving significant attention as it could bring off the shelf-convenience, due to its broader therapeutic spectrum.
The ability of the Dendritic Cancer cell vaccine to provide innate and adaptive immunity, along with providing multiple tumor targeting protection against various Cancer types and overcoming Host’s Self immune tolerant barrier while checking tumor evasion methods has made it the best choice of cancer vaccine among others for the researchers.

Currently 56 Dendritic cell cancer vaccines are in the clinical phase followed by phase II clinical trials. Pfizer, GSK. APAC biotech, Novartis are few companies working on the dendritic cancer vaccine. Only one dendritic cancer cell vaccine is being marketed called Provenge for the treatment of prostate cancer developed by the Dendreon Corporation which became a major success in the dendritic cancer vaccine market. Majority of contribution has been from the rich and developed countries of America and Europe. Japan has slowly begun its research in dendritic cancer vaccine which is still at its nascent stage whereas china has been investing heavily on developing a cancer vaccine irrespective of it being a dendritic cancer cell vaccine.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-and-clinical-trials-outlook-2023.php

High prevalence of cancer and increase in the number of patients diagnosed with cancer has been a major driving factor in the development of the dendritic cancer cell vaccine market. The rise in the toxicity and side effects related to the conventional methods of radiation therapy and chemotherapy has also encouraged researchers and healthcare workers to look for other safer and effective method of treatments. Increased funding from various governmental and non-governmental organizations in the field of dendritic cancer cell vaccine market has been a growth promoting factor for the dendritic cancer cell vaccine market.

Few major obstacles in the dendritic cell cancer vaccine have slowed down the growth of the dendritic cell vaccine market. Challenges are being faced at all the levels. At the scientific level necrosis factor has been a serious challenge for the researchers to overcome. This has further lead to many cancer vaccines to remain at various stages in the clinical pipeline . The poor understanding of the immune system in response to a dendritic cell cancer has been the number one reason. Low availability of dendritic cell in the peripheral blood makes the obtaining of the cells to be studied extremely difficult. The process is sensitive and tedious. Heavy infrastructure required for dendritic cell manufacture has been another reason followed by the standardization of vaccine strategy and its regulation dosage. These Challenges need to be overcome for the dendritic cancer cell vaccine market to flourish and progress rapidly.

Once the challenges faced by the dendritic cancer cell vaccines are dealt with, they are bound to be a blockbuster therapeutic method as this method would have high efficacy compared to the conventional method of radiotherapy and chemotherapy which would slowly be outdated with the advent of dendritic cancer vaccine. In the past few years it has been observed that the cell cancer vaccine segment has been receiving funding support from various agencies globally due to increasing demand of better treatment method of cancer. Increased awareness among people and officials has fuelled the research and development in the cancer vaccine sector thus leading to an encouraged scenario and scope for the cancer vaccine market. Various combinational therapies have positive results at the clinical stage suggesting that the efficacy of the dendritic cell cancer vaccine could be increased with various combinational therapy techniques, this further provided the boost to the cancer vaccine research market These findings would certainly result in the upsurge of the global cancer cell vaccine market and provide the industries working with this segment with immense profits.

Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-and-clinical-trials-outlook-2023.php

For Report Sample Contact: neeraj@kuickresearch.com

Report Table of Contents

1. Advent of Dendritic Vaccine in Oncology
2. Cataloging towards Dendritic Cells
3. Dendritic Cells Mechanizing Immune Response
3.1 Antigen Appearance Leads to Cellular Immune Responses
3.2 Stacking of Distinct Antigens over Dendritic Cells
3.3 Dendritic Cells Source & Subsets
3.4 Trail towards Maturation
3.5 Stimulation Initiates Maturation
3.6 Migration to Lymph Node
3.7 Precision of Dendritic Cells Vaccination
3.8 Illustrations of Clinical Results among Varied Cancer
3.9 Quality Control
3.10 Immune Monitoring
4. Equipping Dendritic Cell Vaccines
4.1 Cross Presentation of CD4 T-CD8 T Cells
4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells
5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens
5.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
5.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
5.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
5.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine
6. Dendritic Cell Cancer Vaccine Market & Clinical Insight
6.1 Some Trends Involving Dendritic Cells Cancer Vaccination
6.2 Dendritic Cell Cancer Vaccine Pipeline Overview
7. Undercurrents of Dendritic Cancer Vaccine Growth
8. Challenging Milieu for Dendritic Cancer Vaccine
9. Prospective Trajectories for Future
10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III
11. Marketed Dendritic Cell Vaccines Clinical Insight
11.1 Sipuleucel-T (Provenge)
11.2 Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC & CreaVax-RCC)
11.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
12. Competitve Landscape
12.1 3M Company
12.2 Activartis
12.3 Argos Therapeutics
12.4 Batavia Bioservices
12.5 Bellicum Pharmaceuticals
12.6 Creagene
12.7 DanDrit Biotech
12.8 DCPrime
12.9 Dendreon Corporation
12.10 Elios Therapeutics
12.11 ImmunoCellular Therapeutics
12.12 Immunicum
12.13 Kiromic
12.14 Medigene
12.15 Merck
12.16 Northwest Biotherapeutics
12.17 Glaxo Smith Kline
12.18 ImmunoCellular Therapeutics
12.19 SOTIO
12.20 Tella Incorporation
12.21 Theravectys
12.22 Vaxil BioTherapeutics

Figure 1-1: Advantages of Dendritic Cell Cancer Vaccine
Figure 2-1: Classification of Dendritic Cells
Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
Figure 3-2: The Key Players Intricately Involved in Antigen Presentation & Immune Response Machinery
Figure 3-3: Process of Antigen-loading
Figure 3-4: Major Life Cycle Events of a Dendritic Cell
Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
Figure 5-1: Working Principle Targeted By Dendritic Cells & Monoclonal Antibodies
Figure 5-2: Working Principle Targeted by Dendritic Cells & Peptide Cancer Vaccines
Figure 5-3: Working Principle Targeted by Dendritic Cells & Cytokine Cancer Vaccine
Figure 5-4: Working Principle Targeted By Dendritic Cells & Antibody-Drug Conjugates Cancer Vaccines
Figure 6-1: Recent Trends in Dendritic Cell Vaccine
Figure 6-2: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (%), 2017 till 2023
Figure 6-3: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 6-4: Global – Suspended Dendritic Cell Vaccine in Clinical Pipeline by Phase (%), 2017 till 2023
Figure 6-5: Global – Suspended Dendritic Cell Vaccine in Pipeline by Phase (Number), 2017 till 2023
Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
Figure 12-1: Argos Therapeutics- Clinical Pipeline
Figure 12-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 12-3: DCPrime Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: Immunicum Clinical Pipeline
Figure 12-6: Medigene Clinical Pipeline
Figure 12-7: Northwest Biotherapeutics Clinical Pipeline
Figure 12-8: SOTIO Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.